Prime editing system based on PERV reverse transcriptase

By using PERV-NC fusion RNase H structure to delete and carry multiple mutation sites instead of MMLV-RT in the PE2 editor, the problem of inefficient editing in mammalian cells in the prior art is solved, and the problem of inefficient editing in mammalian cells is achieved. More efficient pilot editing effects.

WO2024240138A1PCT designated stage expired Publication Date: 2024-11-28JIANGXI AGRICULTURAL UNIVERSITY +1

Patent Information

Application Number
PCT/CN2024/094408
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing pilot editing systems are less efficient in mammalian cells, especially when using other types of reverse transcriptases, which are significantly less efficient than PE2, and fail to significantly improve editing efficiency in mammalian cells.

Method used

PERV-RT, which uses PERV-NC fusion RNase H structure to delete and carry multiple mutation sites, replaces MMLV-RT in the PE2 editor to improve the efficiency of pilot editing in mammals.

Benefits of technology

The editing efficiency in mammalian cells was significantly improved, especially through the PERV-RT-derived epPE editor in different cell lines, and the editing efficiency was higher than that of the PE2c-Puro editor in mouse RT, and the epPE-AC-M3Δ- Puro and epPE-AC-M4Δ*-Puro are better than epPE-B-M3Δ-Puro and epPE-B-M4Δ*-Puro.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024094408-FTAPPB-I100001
    Figure PCTCN2024094408-FTAPPB-I100001
  • Figure PCTCN2024094408-FTAPPB-I100002
    Figure PCTCN2024094408-FTAPPB-I100002
  • Figure PCTCN2024094408-FTAPPB-I100003
    Figure PCTCN2024094408-FTAPPB-I100003
Patent Text Reader

Abstract

Disclosed are a prime editing system based on a PERV reverse transcriptase (RT), and a method for gene editing by means of the system, relating to the field of genetic engineering. More specifically, provided are: 1, a prime editing system fusing a PERV-NC with a PERV-RT having an RNase H structure deleted and carrying a plurality of mutation sites; 2, a pegRNA fused with truncated Csy4 (tCsy4-pegRNA); and 3, one or more small molecule compounds for treating cells and a combinations thereof. Thus, the efficiency of prime editing in mammals is improved.
Need to check novelty before this filing date? Find Prior Art

Description

PERV reverse transcriptase-based prime editing system Technical Field

[0001] The present invention relates to the field of genetic engineering. Specifically, the present invention relates to a PERV reverse transcriptase-based lead editing system and a method for gene editing using the system.

[0002] Background of the Invention

[0003] Prime editing (PE) is a novel gene editing technology that has emerged in recent years. It can achieve a variety of editing types, including point mutations, insertions, deletions, and substitutions, without inducing double-strand breaks in DNA. This overcomes the major limitations of current CRISPR / Cas9 and single-base editing technologies and is currently the most precise genome editing technology. The PE editing system consists of a PE editor and a prime editing guide RNA (pegRNA and / or ngRNA). The PE editor is the most critical component of prime editing and consists of a fusion of the Cas9 single-nickase (nCas9 H840A) and a reverse transcriptase (RT). The currently highly efficient and widely used PE2 and its improved version, PEmax, utilize the Moloney murine leukemia virus reverse transcriptase (MMLV-RT) carrying five mutations: D200N, L603W, T330P, T306K, and W313F.

[0004] Some teams have used other types of RT for lead editing, but their efficiency is lower or significantly lower than PE2. Other reports have shown that fusing the nucleocapsid protein (NC) to RT can help improve lead editing efficiency. By fusing the MMLV nucleocapsid protein (NC) to MMLV-RT (without the RNase H structure) (MMLV-RT (ΔRNase H)), an efficiency-enhanced PE editor, ePPE, was developed. However, reports to date have shown that ePPE only significantly improves editing efficiency in plant cells, but not in mammalian cells.

[0005] There is still a need in the art for efficient prime editing systems, particularly prime editing systems that can perform efficient editing in mammalian cells.

[0006] Summary of the Invention

[0007] The present invention uses PERV-NC fused with RNase H structure deletion and carrying multiple mutation sites to replace MMLV-RT in the PE2 editor to improve the efficiency of lead editing in mammals.

[0008] BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 shows the amino acid sequence alignment of MMLV-RT (ΔRNase H), PERV-AC-RT (ΔRNase H), and PERV-B-RT (ΔRNase H).

[0010] Figure 2. Schematic diagram of the vectors of the PERV reverse transcriptase editors of different NCBI sequences of the present invention.

[0011] Figure 3. Shows the editing efficiency of PE2c-Puro, epPE-B-M3Δ-Puro, and epPE-B-M4Δ*-Puro editors in the BFP reporter cell line.

[0012] Figure 4. Shows the editing efficiency of PE2c-Puro and epPE-M3Δ-Puro editors in primary PFFs.

[0013] FIG5 shows the editing efficiency of PE2c-Puro and epPE-AC-M3Δ-Puro editors in HEK293T, canine fetal fibroblasts (DFF), and sheep fetal fibroblasts (SFF) cells.

[0014] Figure 6. Schematic diagram of the vectors based on different Bama Xiang pig PERV reverse transcriptase editors of the present invention.

[0015] Figure 7. Shows the editing activity of the pPE editor containing four point mutations and wild-type Bama Xiang pig PERV reverse transcriptase in the BFP reporter gene cell line.

[0016] Figure 8 shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in PFF.

[0017] Figure 9 shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in HEK293T, canine fetal fibroblasts (DFF), and sheep fetal fibroblasts (SFF).

[0018] Figure 10. Shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase epPE editor in PFF based on four point mutations.

[0019] Figure 11. Shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase epPE editor based on four point mutations in HEK293T, canine fetal fibroblasts (DFF), and sheep fetal fibroblasts (SFF).

[0020] Figure 12 shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 1-6 point mutations when co-transfected with a fluorescent reporter gene in HEK293T cells.

[0021] Figure 13. Shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor based on M5.1 superimposed with different point mutations in HEK293T cells.

[0022] Figure 14 shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor based on 7 point mutations in HEK293T cells.

[0023] Figure 15 shows the editing efficiency of the epPE editor based on 7 point mutations of Bama Xiang pig PERV reverse transcriptase in HEK293T cells.

[0024] Figure 16 shows the efficiency of the epPE editor based on the Bama Xiang pig PERV reverse transcriptase with 7 point mutations compared with PEmax, PE6c and PE6d.

[0025] Figure 17. Shows that Csy4 and tCsy4-pegRNA improve the editing efficiency of PE editor.

[0026] Figure 18. Shows that small molecule compounds enhance the editing efficiency of PE editors.

[0027] Detailed Description of the Invention

[0028] 1. Definition

[0029] In the present invention, unless otherwise indicated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are terms and routine procedures widely used in the corresponding fields. For example, the standard recombinant DNA and molecular cloning techniques used in the present invention are well known to those skilled in the art and are more fully described in the following literature: Sambrook, J., Fritsch, EF and Maniatis, T., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter referred to as "Sambrook"). At the same time, in order to better understand the present invention, definitions and explanations of relevant terms are provided below.

[0030] As used herein, the term "and / or" encompasses all combinations of items connected by the term, and should be treated as if each combination had been individually listed herein. For example, "A and / or B" encompasses "A," "A and B," and "B." For example, "A, B, and / or C" encompasses "A," "B," "C," "A and B," "A and C," "B and C," and "A and B and C."

[0031] When the word "comprising" is used herein to describe a sequence of a protein or nucleic acid, the protein or nucleic acid may be composed of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleic acid, but still have the activity described in the present invention. In addition, it is clear to those skilled in the art that the methionine encoded by the start codon at the N-terminus of the polypeptide may be retained in certain practical situations (for example, when expressed in a specific expression system), but it does not substantially affect the function of the polypeptide. Therefore, when describing a specific polypeptide amino acid sequence in the specification and claims of this application, although it may not contain a methionine encoded by a start codon at the N-terminus, a sequence containing the methionine is also covered, and accordingly, its encoding nucleotide sequence may also contain a start codon; and vice versa.

[0032] "Genome" as used herein encompasses not only the chromosomal DNA present in the nucleus of a cell, but also the organelle DNA present in subcellular components of the cell (eg, mitochondria, plastids).

[0033] As used herein, "organism" includes any organism suitable for genome editing, preferably a eukaryotic organism. Examples of organisms include, but are not limited to, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, and cats; poultry such as chickens, ducks, and geese; and plants, including monocots and dicots, such as rice, corn, wheat, sorghum, barley, soybeans, peanuts, and Arabidopsis.

[0034] "Genetically modified organism" means an organism that contains an exogenous polynucleotide or a modified gene or expression control sequence within its genome. For example, the exogenous polynucleotide is capable of stably integrating into the genome of the organism and being inherited through successive generations. The exogenous polynucleotide can be integrated into the genome alone or as part of a recombinant DNA construct. A modified gene or expression control sequence is one that contains one or more nucleotide substitutions, deletions, and additions in the genome of the organism.

[0035] "Exogenous" with respect to a sequence refers to a sequence that is from a foreign species, or, if from the same species, has been significantly altered from its native form in composition and / or locus through deliberate human intervention.

[0036] "Polynucleotide," "nucleic acid sequence," "nucleotide sequence," or "nucleic acid fragment" are used interchangeably and are single-stranded or double-stranded polymers of RNA or DNA that optionally contain synthetic, non-natural, or altered nucleotide bases. Nucleotides are referred to by their single-letter designations as follows: "A" for adenosine or deoxyadenosine (RNA or DNA, respectively), "C" for cytidine or deoxycytidine, "G" for guanosine or deoxyguanosine, "U" for uridine, "T" for deoxythymidine, "R" for purine (A or G), "Y" for pyrimidine (C or T), "K" for G or T, "H" for A or C or T, "D" for A, T, or G, "I" for inosine, and "N" for any nucleotide. Although nucleotide sequences herein may be presented as DNA sequences (including T), when reference is made to RNA, one skilled in the art can readily determine the corresponding RNA sequence (i.e., replacing T with U).

[0037] "Polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues is an artificial chemical analog of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The terms "polypeptide," "peptide," "amino acid sequence," and "protein" may also include modified forms including, but not limited to, glycosylation, lipid attachment, sulfation, gamma carboxylation of glutamic acid residues, hydroxylation, and ADP-ribosylation.

[0038] Sequence "identity" has a meaning recognized in the art, and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the entire length of a polynucleotide or polypeptide or along a region of the molecule. (See, for example: Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there are many methods to measure the identity between two polynucleotides or polypeptides, the term "identity" is well known to those of skill in the art (Carrillo, H. & Lipman, D., SIAM J Applied Math 48: 1073 (1988)).

[0039] As used herein, "amino acid position referenced to SEQ ID NO: x" (SEQ ID NO: x is a specific sequence listed herein) means that the position number of the specific amino acid being described is the position number of the amino acid corresponding to that amino acid on SEQ ID NO: x. The correspondence of amino acids in different sequences can be determined according to sequence alignment methods known in the art. For example, amino acid correspondence can be determined by the online alignment tool of EMBL-EBI (https: / / www.ebi.ac.uk / Tools / psa / ), where two sequences can be aligned using the Needleman-Wunsch algorithm using default parameters. For example, if the alanine at position 360 from the N-terminus of a polypeptide is aligned with the amino acid at position 365 of SEQ ID NO: x in a sequence alignment, then the alanine amino acid in the polypeptide may also be described herein as "the alanine at position 365 of the polypeptide, said amino acid position referenced to SEQ ID NO: x".

[0040] As used herein, an "expression construct" refers to a vector, such as a recombinant vector, suitable for expressing a nucleotide sequence of interest in an organism. "Expression" refers to the production of a functional product. For example, expression of a nucleotide sequence can refer to the transcription of the nucleotide sequence (e.g., transcription to produce mRNA or functional RNA) and / or translation of RNA into a precursor or mature protein.

[0041] The "expression construct" of the present invention can be a linear nucleic acid fragment, a circular plasmid, a viral vector, or, in some embodiments, can be a translatable RNA (e.g., mRNA), for example, RNA generated by in vitro transcription. For use in mammals such as humans, the expression construct is preferably a viral vector, such as an adeno-associated virus (AAV), a lentivirus, or an adenoviral vector, with an AAV vector being most preferred.

[0042] An "expression construct" of the present invention may comprise regulatory sequences and a nucleotide sequence of interest from different sources, or regulatory sequences and a nucleotide sequence of interest from the same source but arranged in a manner different from that normally found in nature.

[0043] "Promoter" refers to a nucleic acid fragment that is capable of controlling the transcription of another nucleic acid fragment. In some embodiments of the present invention, a promoter is a promoter that is capable of controlling the transcription of a gene in a cell, whether or not derived from the cell. A promoter can be a constitutive promoter, a tissue-specific promoter, a developmentally regulated promoter, or an inducible promoter.

[0044] Examples of promoters include, but are not limited to, polymerase pol I, pol II, or pol III promoters. Examples of pol I promoters include the chicken RNA pol I promoter. Examples of pol II promoters include, but are not limited to, the cytomegalovirus immediate early (CMV) promoter, the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter, and the simian virus 40 (SV40) immediate early promoter. Examples of pol III promoters include the U6, U3, and H1 promoters. Inducible promoters such as the metallothionein promoter can be used. Other examples of promoters include the T7 phage promoter, the T3 phage promoter, the β-galactosidase promoter, and the Sp6 phage promoter. When used in plants, the promoter can be the cauliflower mosaic virus 35S promoter, the maize Ubi-1 promoter, the wheat U6 promoter, the rice U3 promoter, the maize U3 promoter, or the rice actin promoter.

[0045] "Introducing" a nucleic acid molecule (e.g., a plasmid, a linear nucleic acid fragment, RNA, etc.) or a protein into an organism refers to transforming the cells of the organism with the nucleic acid or protein so that the nucleic acid or protein can function in the cell. "Transformation" as used in the present invention includes stable transformation and transient transformation. "Stable transformation" refers to the introduction of an exogenous nucleotide sequence into the genome, resulting in the stable inheritance of the exogenous gene. Once stably transformed, the exogenous nucleic acid sequence is stably integrated into the genome of the organism and any successive generations thereof. "Transient transformation" refers to the introduction of a nucleic acid molecule or protein into a cell to perform a function without the stable inheritance of the exogenous gene. In transient transformation, the exogenous nucleic acid sequence is not integrated into the genome.

[0046] "Trait" refers to a physiological, morphological, biochemical, or physical characteristic of a cell or organism.

[0047] 2. Reverse transcriptase from PERV and its variants

[0048] In one aspect, the present invention provides a reverse transcriptase from a porcine endogenous retrovirus (PERV) or a functional variant thereof. The reverse transcriptase has reverse transcription activity that generates a complementary DNA chain using a single-stranded RNA as a template, while its functional variant substantially retains or has enhanced reverse transcription activity. The reverse transcriptase from PERV or its functional variant described in the present invention can be used for lead editing, particularly for lead editing in mammalian cells.

[0049] In some embodiments, the reverse transcriptase from PERV (also referred to herein as PERV reverse transcriptase) is from type A, type B, or type C PERV, or from a recombinant of a different type of PERV, such as a type A / C PERV recombinant.

[0050] In some embodiments, the PERV is a PERV isolated from Bama Xiang pig. In some embodiments, the PERV is isolated from other breeds of pigs.

[0051] In some embodiments, the PERV reverse transcriptase or a functional variant thereof comprises an amino acid sequence of one of SEQ ID NOs: 1-5, or an amino acid sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even 100% sequence identity to one of SEQ ID NOs: 1-5.

[0052] In some embodiments, the functional variant of the PERV reverse transcriptase lacks the RNase H domain. The RNase H domain of the PERV reverse transcriptase, for example, comprises an amino acid sequence corresponding to about position 514 to about position 616 of SEQ ID NO: 1.

[0053] In some embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid substitution at one or more positions selected from position 63, 199, 222, 305, 312, 329, 330, 331, 332, 408, or 602.

[0054] When referring to the amino acid position of PERV reverse transcriptase or a functional variant thereof herein, the amino acid position is with reference to SEQ ID NO:5.

[0055] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, and 312. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, and W312F.

[0056] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, and L602W.

[0057] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, and 332. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, and E332C.

[0058] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, 332, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, E332C, and L602W.

[0059] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, and L602W.

[0060] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, and L602W.

[0061] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, C408R, and L602W.

[0062] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, C408R, and L602W.

[0063] In some specific embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6 (corresponding to AC-RT-M0Δ), SEQ ID NO: 7 (corresponding to AC-RT-M3Δ), SEQ ID NO: 8 (corresponding to AC-RT-M4Δ*), SEQ ID NO: 9 (corresponding to B-RT-M0Δ), SEQ ID NO: 10 (corresponding to B-RT-M3Δ), SEQ ID NO: 11 (corresponding to B-RT-M4Δ*), and SEQ ID NO: 12 (corresponding to bmx-A-RT-M4), SEQ ID NO: 13 (corresponding to bmx-B-RT-M4), SEQ ID NO: 14 (corresponding to bmx-C-RT-M4), SEQ ID NO: 15 (corresponding to bmx-A-RT-M3Δ), SEQ ID NO: 16 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 17 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 18 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 19 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 20 (corresponding to bmx-A-RT-M4), SEQ ID NO: 21 (corresponding to bmx-B-RT-M4), SEQ ID NO: 22 (corresponding to bmx-C-RT-M4), SEQ ID NO: 23 (corresponding to bmx-A-RT-M3Δ), SEQ ID NO: 24 (corresponding to bmx- NO:40 (corresponding to bmx-C-RT-M5.1), SEQ ID NO:41 (corresponding to bmx-C-RT-M5.1+Y63R), SEQ ID NO:42 (corresponding to bmx-C-RT-M5.1+C408R), SEQ ID NO:43 (corresponding to bmx-C-RT-M7) and SEQ ID NO:44 (corresponding to bmx-C-RT-M7Δ).

[0064] In another aspect, the present invention provides use of the reverse transcriptase from PERV or a functional variant thereof according to the present invention for lead editing, in particular for use in lead editing in mammalian cells.

[0065] The "mammal" described herein includes but is not limited to humans, mice, rats, monkeys, dogs, pigs, sheep, cows, cats, etc. In some preferred embodiments, the mammal is a pig. In some preferred embodiments, the mammal is a human.

[0066] 3. Prime editing system based on reverse transcriptase from PERV

[0067] In one aspect, the present invention relates to a prime editing system for targeted modification of a genomic DNA sequence in an organism, comprising:

[0068] i) a CRISPR nuclease, such as a CRISPR nickase, and / or an expression construct comprising a nucleotide sequence encoding said CRISPR nuclease, such as a CRISPR nickase, and a PERV reverse transcriptase or a functional variant thereof and / or an expression construct comprising a nucleotide sequence encoding said PERV reverse transcriptase or a functional variant thereof; and / or

[0069] ii) at least one pegRNA and / or an expression construct containing a nucleotide sequence encoding said at least one pegRNA.

[0070] In some embodiments, the at least one pegRNA comprises, from 5' to 3' direction, a leader sequence, a scaffold sequence, a reverse transcription template (RTT) sequence, and a primer binding site (PBS) sequence.

[0071] In some embodiments, the CRISPR nuclease, such as a CRISPR nickase, and the PERV reverse transcriptase or a functional variant thereof form a fusion protein.

[0072] In one aspect, the present invention relates to a prime editing system for targeted modification of a genomic DNA sequence in an organism, comprising:

[0073] i) a lead editing fusion protein and / or an expression construct containing a nucleotide sequence encoding the lead editing fusion protein, wherein the lead editing fusion protein comprises a CRISPR nuclease, such as a CRISPR nickase, and a PERV reverse transcriptase, or a functional variant thereof; and / or

[0074] ii) at least one pegRNA and / or an expression construct containing a nucleotide sequence encoding said at least one pegRNA.

[0075] In some embodiments, the at least one pegRNA comprises, from 5' to 3' direction, a leader sequence, a scaffold sequence, a reverse transcription template (RTT) sequence, and a primer binding site (PBS) sequence.

[0076] On the other hand, the present invention also provides a lead editing fusion protein comprising a CRISPR nuclease such as a CRISPR nickase and a PERV reverse transcriptase or a functional variant thereof. The present invention also provides the use of the lead editing fusion protein for lead editing, particularly for use in lead editing in mammalian cells.

[0077] In some embodiments, the CRISPR nuclease, such as a CRISPR nickase, and the PERV reverse transcriptase or a functional variant thereof in the lead editing fusion protein are connected via a linker.

[0078] In some embodiments, the at least one pegRNA is capable of forming a complex with the CRISPR nuclease, such as a CRISPR nickase, the PERV reverse transcriptase, or a functional variant thereof, and targeting the fusion protein to a target sequence in the genome, resulting in a nick within the target sequence.

[0079] In some embodiments, the at least one pegRNA is capable of forming a complex with the fusion protein and targeting the fusion protein to a target sequence in the genome, resulting in a nick within the target sequence.

[0080] As used herein, "prime editing system" refers to a combination of components required for reverse transcription-based genome editing of the genome in a cell. The individual components of the system, such as CRISPR nucleases such as CRISPR nickases, PERV reverse transcriptases or functional variants thereof, prime editing fusion proteins, pegRNAs, etc., can exist independently or in any combination as a composition.

[0081] As used herein, "target sequence" refers to a sequence of about 20 nucleotides in length characterized by a PAM (protospacer adjacent motif) sequence on the 5' or 3' flank in the genome. Generally speaking, a PAM is necessary for the complex formed by the CRISPR nuclease or its variants and the guide RNA to recognize the target sequence. For example, for the Cas9 nuclease and its variants, the target sequence is adjacent to the PAM at the 3' end, such as 5'-NGG-3'. Based on the presence of the PAM, those skilled in the art can easily determine the target sequence that can be used for targeting in the genome. And depending on the position of the PAM, the target sequence can be located on either chain of the genomic DNA molecule. For Cas9 or its derivatives such as Cas9 nickase, the target sequence is preferably 20 nucleotides.

[0082] The CRISPR nucleases of the present invention may be CRISPR nucleases of different origins. Examples of CRISPR nucleases suitable for the present invention include, but are not limited to, Cas9, Cas12a (i.e., Cpf1), Cas12b (i.e., C2c1), Cas12c, Cas12d (i.e., CasY), Cas12e (i.e., CasX), Cas12f (i.e., Cas14), Cas12h, Cas12i, Cas12j (i.e., CasΦ), Cas12k, Cas12m, IsrB, IscB, and TnpB.

[0083] In some embodiments, the CRISPR nuclease also includes a nickase form thereof. The CRISPR nuclease in the form of a nickase may also be referred to herein as a CRISPR nickase, which forms a nick in only one strand of a double-stranded nucleic acid molecule, but does not completely cut off the double-stranded nucleic acid. In some embodiments, the CRISPR nickase is capable of forming a nick within a target sequence in genomic DNA. Those skilled in the art can obtain nickase forms of different CRISPR nucleases, for example, by mutating the nucleic acid cleavage domain of the CRISPR nuclease.

[0084] In some embodiments, the CRISPR nickase is a Cas9 nickase. However, the CRISPR nickase can also be derived from other CRISPR nucleases.

[0085] In some embodiments, the Cas9 nickase is derived from SpCas9 of Streptococcus pyogenes (S. pyogenes) and comprises at least the amino acid substitution H840A relative to wild-type SpCas9. In some embodiments, the Cas9 nickase comprises the amino acid sequence shown in SEQ ID NO: 18. In some embodiments, the Cas9 nickase in the fusion protein is capable of forming a nick between the -3 nucleotide (the first nucleotide at the 5' end of the PAM sequence is the +1 position) and the -4 nucleotide of the PAM of the target sequence.

[0086] In some embodiments, the Cas9 nickase is a Cas9 nickase variant that can recognize an altered PAM sequence. Many Cas9 nickase variants that can recognize an altered PAM sequence are known in the art. For example, the Cas9 nickase is a Cas9 variant that recognizes the PAM sequence 5'-NG-3'. These different variants can all be applied to the present invention.

[0087] The nick formed by the Cas9 nickase of the present invention can cause the target sequence to form a free single strand with a 3' end (3' free single strand) and a free single strand with a 5' end (5' free single strand).

[0088] In some embodiments, the PERV reverse transcriptase or a functional variant thereof in the fusion protein is the PERV reverse transcriptase or a functional variant thereof described above in the present invention.

[0089] In some embodiments, the PERV reverse transcriptase is from a type A, type B, or type C PERV, or from a recombinant of a different type of PERV, such as a type A / C PERV recombinant.

[0090] In some embodiments, the PERV is a PERV isolated from Bama Xiang pig. In some embodiments, the PERV is isolated from other breeds of pigs.

[0091] In some embodiments, the PERV reverse transcriptase or a functional variant thereof comprises an amino acid sequence of one of SEQ ID NOs: 1-5, or an amino acid sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even at least 100% sequence identity to one of SEQ ID NOs: 1-5.

[0092] In some embodiments, the functional variant of the PERV reverse transcriptase lacks the RNase H domain. The RNase H domain of the PERV reverse transcriptase, for example, comprises an amino acid sequence corresponding to about position 514 to about position 616 of SEQ ID NO:5.

[0093] In some embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid substitution at one or more positions selected from position 199, 305, 312, 329, 330, 331, 332, or 602.

[0094] When referring to the amino acid positions of PERV reverse transcriptase or a functional variant thereof herein, the amino acid positions are referenced to SEQ ID NO: 1.

[0095] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, and 312. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, and W312F.

[0096] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, and L602W.

[0097] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, and 332. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, and E332C.

[0098] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, 332, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, E332C, and L602W.

[0099] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, and L602W.

[0100] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, and L602W.

[0101] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, C408R, and L602W.

[0102] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, C408R, and L602W.

[0103] In some specific embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6 (corresponding to AC-RT-M0Δ), SEQ ID NO: 7 (corresponding to AC-RT-M3Δ), SEQ ID NO: 8 (corresponding to AC-RT-M4Δ*), SEQ ID NO: 9 (corresponding to B-RT-M0Δ), SEQ ID NO: 10 (corresponding to B-RT-M3Δ), SEQ ID NO: 11 (corresponding to B-RT-M4Δ*), and SEQ ID NO: 12 (corresponding to bmx-A-RT-M4), SEQ ID NO: 13 (corresponding to bmx-B-RT-M4), SEQ ID NO: 14 (corresponding to bmx-C-RT-M4), SEQ ID NO: 15 (corresponding to bmx-A-RT-M3Δ), SEQ ID NO: 16 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 17 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 18 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 19 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 20 (corresponding to bmx-A-RT-M4), SEQ ID NO: 21 (corresponding to bmx-B-RT-M4), SEQ ID NO: 22 (corresponding to bmx-C-RT-M4), SEQ ID NO: 23 (corresponding to bmx-A-RT-M3Δ), SEQ ID NO: 24 (corresponding to bmx- NO:40 (corresponding to bmx-C-RT-M5.1), SEQ ID NO:41 (corresponding to bmx-C-RT-M5.1+Y63R), SEQ ID NO:42 (corresponding to bmx-C-RT-M5.1+C408R), SEQ ID NO:43 (corresponding to bmx-C-RT-M7) and SEQ ID NO:44 (corresponding to bmx-C-RT-M7Δ).

[0104] In some embodiments, in the fusion protein, the reverse transcriptase or a functional variant thereof is fused to a nucleocapsid protein (NC) directly or via a linker at the N-terminus or C-terminus. The nucleocapsid protein (NC) is, for example, derived from PERV. Preferably, the nucleocapsid protein and the reverse transcriptase are derived from the same type of PERV.

[0105] In some embodiments, the nucleocapsid protein comprises the amino acid sequence shown in SEQ ID NO: 19 or one of SEQ ID NOs: 36-39.

[0106] In some embodiments, the PERV reverse transcriptase or a functional variant thereof is fused to the nucleocapsid protein (NC) at the N-terminus, either directly or through a linker.

[0107] In some embodiments, the PERV reverse transcriptase or a functional variant thereof is fused to the nucleocapsid protein (NC) at the C-terminus, either directly or through a linker.

[0108] As used herein, a "linker" can be a non-functional amino acid sequence of 1-50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 20-25, 25-50) or more amino acids in length, without secondary or higher structure. For example, the linker can be a flexible linker, etc. For example, it can be an XTEN linker as set forth in SEQ ID NO: 20.

[0109] In some embodiments, the CRISPR nuclease, such as a CRISPR nickase, in the fusion protein is located at the N-terminus of the reverse transcriptase and / or nucleocapsid protein. In some embodiments, the CRISPR nuclease, such as a CRISPR nickase, in the fusion protein is located at the C-terminus of the reverse transcriptase and / or nucleocapsid protein.

[0110] In some embodiments of the present invention, the fusion protein of the present invention may further include a nuclear localization sequence (NLS). Generally speaking, the one or more NLS in the fusion protein should have sufficient strength to drive the fusion protein in the nucleus of the cell to accumulate in an amount that can realize its base editing function. Generally speaking, the intensity of nuclear localization activity is determined by the number, position, one or more specific NLS used in the fusion protein or a combination of these factors. However, depending on the DNA position required to be edited, the lead editing fusion protein of the present invention may also include one or more other localization sequences, such as cytoplasmic localization sequences, chloroplast localization sequences, mitochondrial localization sequences, etc.

[0111] In some embodiments, the fusion protein may further include a selectable marker protein linked directly or via a self-cleavable peptide.

[0112] As used herein, "self-cleaving peptide" means a peptide that can achieve self-cleavage in cells. For example, the self-cleaving peptide can contain a protease recognition site, thereby being recognized and specifically cleaved by a protease in the cell.

[0113] Alternatively, the self-cleaving peptide can be a 2A polypeptide. 2A polypeptides are a class of short peptides from viruses, and their self-cleavage occurs during translation. When two different target proteins are expressed in the same reading frame using a 2A polypeptide, two target proteins are generated at almost a 1:1 ratio. Commonly used 2A polypeptides can be P2A from porcine techovirus-1, T2A from Thosea asigna virus, E2A from equine rhinitis A virus, and F2A from foot-and-mouth disease virus. Among them, P2A has the highest cleavage efficiency and is therefore preferred. A variety of functional variants of these 2A polypeptides are also known in the art, and these variants can also be used in the present invention.

[0114] An exemplary selectable marker protein is, for example, Puro-R protein. Puro-R protein can provide puromycin resistance for selection of positive cells. An exemplary Puro-R protein comprises the amino acid sequence shown in SEQ ID NO: 35.

[0115] In some specific embodiments, the fusion protein comprises the amino acid sequence shown in one of SEQ ID NOs: 22-34 and 45-49.

[0116] The leader sequence (also called seed sequence or spacer sequence) in at least one pegRNA of the present invention is set to have sufficient sequence identity (preferably 100% identity) with the target sequence, so that it can bind to the complementary chain of the target sequence through base pairing to achieve sequence-specific targeting.

[0117] A variety of scaffold sequences suitable for gRNAs for genome editing based on CRISPR nucleases (e.g., Cas9) are known in the art and can be used in the pegRNA of the present invention. In some embodiments, the scaffold sequence of the gRNA is shown in SEQ ID NO: 21.

[0118] In some embodiments, the primer binding sequence (PBS) is configured to be complementary to at least a portion of the target sequence (preferably completely paired with at least a portion of the target sequence). Preferably, the primer binding sequence is complementary to at least a portion of the 3' free single strand resulting from the nick in the DNA chain containing the target sequence (preferably completely paired with at least a portion of the 3' free single strand), in particular, complementary to the nucleotide sequence at the 3' end of the 3' free single strand (preferably completely paired with). When the 3' free single strand of the chain binds to the primer binding sequence through base pairing, the 3' free single strand can serve as a primer, using the reverse transcription template (RTT) sequence immediately adjacent to the primer binding sequence as a template, and reverse transcription is performed under the action of the reverse transcriptase or a functional variant thereof in the fusion protein, thereby extending a DNA sequence corresponding to the reverse transcription (RT) template sequence.

[0119] The primer binding sequence depends on the length of the free single strand formed by the CRISPR nickase used in the target sequence, however, it should have a minimum length to ensure specific binding. In some embodiments, the primer binding sequence length can be 4-20 nucleotides, for example, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides in length.

[0120] The RT template sequence described herein can be any sequence. Through the above-mentioned reverse transcription, its sequence information can be integrated into the DNA chain where the target sequence is located (i.e., the chain containing the target sequence PAM), and then through the DNA repair function of the cell, a DNA double strand containing the RT template sequence information is formed. In some embodiments, the RT template sequence contains a desired modification. For example, the desired modification includes the substitution, deletion and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions.

[0121] In some embodiments, the RT template sequence is set to a sequence corresponding to the target sequence nick downstream (e.g., complementary to at least a portion of the sequence downstream of the target sequence nick), and includes a desired modification. The desired modification includes substitution, deletion, and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions.

[0122] In some embodiments, the RT template sequence can be about 1-300 or more nucleotides in length, for example, 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300 nucleotides or more in length. Preferably, the RT template sequence is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 nucleotides in length.

[0123] In some embodiments, the lead editing system further comprises a nicking gRNA (nicking gRNA, for generating additional nicks) and / or an expression construct containing a nucleotide sequence encoding the nicking gRNA, wherein the nicking gRNA comprises a leader sequence and a scaffold sequence. In some preferred embodiments, the nicking gRNA does not comprise a reverse transcription (RT) template sequence and a primer binding site (PBS) sequence.

[0124] The leader sequence (also known as seed sequence or spacer sequence) in the nicking gRNA of the present invention is set to have sufficient sequence identity (preferably 100% identity) with the nicking target sequence in the genome, so that the fusion protein of the present invention can be targeted to the nicking target sequence and cause a nick in the nicking target sequence, and the nicking target sequence and the target sequence targeted by the pegRNA (pegRNA target sequence) are located on the opposite strand of the genomic DNA. In some embodiments, the nick formed by the nicking RNA and the nick formed by the pegRNA are about 1 to about 300 or more nucleotides apart, for example, 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300 nucleotides or more nucleotides apart. In some embodiments, the nick formed by the nicking RNA is located upstream or downstream of the pegRNA formation (the upstream or downstream are both referenced to the DNA chain where the pegRNA target sequence is located). In some embodiments, the leader sequence in the nicking gRNA has sufficient sequence identity (preferably 100% identity) with the relative chain (modified) of the pegRNA target sequence after the editing event occurs, so that the nicking gRNA only targets the nicking target sequence generated after the pegRNA-induced target sequence targeting and modification are completed. In some embodiments, the PAM of the nicking target sequence is located within the complementary sequence of the pegRNA target sequence.

[0125] In some embodiments, the lead editing system comprises at least one pair of pegRNA and / or an expression construct containing a nucleotide sequence encoding the at least one pair of pegRNA. In some embodiments, the two pegRNAs in the pegRNA pair are set to target different target sequences on the same chain of the genomic DNA. In some embodiments, the two pegRNAs in the pegRNA pair are set to target sequences on different chains of the genomic DNA. In some embodiments, the PAM of the target sequence of one pegRNA in the pegRNA pair is located in the sense strand, while the PAM of the other pegRNA is located in the antisense strand. In some embodiments, the induced nicks of the two pegRNAs are located on both sides of the site to be modified. In some embodiments, the nick induced by the pegRNA for the sense strand is located upstream (5' direction) of the site to be modified, and the nick induced by the pegRNA for the antisense strand is located downstream (3' direction) of the site to be modified. The upstream or downstream is relative to the sense strand. In some embodiments, the nicks induced by the two pegRNAs are about 1 to about 300 or more nucleotides apart, such as 1-15 nucleotides apart.

[0126] In some embodiments, the two pegRNAs in the pegRNA pair are configured to introduce the same desired modification. For example, one pegRNA is configured to introduce an A to G substitution in the sense strand, while the other pegRNA is configured to introduce a T to C substitution in the corresponding position of the antisense strand. For another example, one pegRNA is configured to introduce a deletion of two nucleotides in the sense strand, while the other pegRNA is configured to also introduce a deletion of two nucleotides in the corresponding position of the antisense strand. Other types of modifications can be deduced by analogy. The same desired modification can be achieved by designing a suitable RT template sequence to enable the pegRNAs targeting two different chains to achieve the same desired modification.

[0127] In some preferred embodiments, the pegRNA of the present invention is epegRNA. The construction of epegRNA can refer to James W. Nelson et al., Engineered pegRNAs improve prime editing efficiency. Nature Biotechnology volume 40, 402–410 (2022), which is incorporated herein by reference. In some embodiments, the epegRNA is an epegRNA with a 3'-tevopreQ1-8nt linker modification.

[0128] In some preferred embodiments, pegRNA of the present invention is Csy4-pegRNA.Csy4-pegRNA comprises Csy4 recognition sequence at the 3' end of pegRNA, for example, the Csy4 recognition sequence shown in SEQ ID NO:50.

[0129] In some preferred embodiments, pegRNA of the present invention is tCsy4-pegRNA.TCsy4-pegRNA comprises the Csy4 recognition sequence of brachiation at the 3 ' end of pegRNA, for example the Csy4 recognition sequence of brachiation shown in SEQ ID NO:51.

[0130] In order to achieve effective expression in different organisms, in some embodiments of the present invention, the nucleotide sequence encoding the fusion protein is codon-optimized for the organism species whose genome is to be modified.

[0131] Codon optimization refers to the method for modifying nucleic acid sequence to enhance the expression in the host cell of interest by replacing at least one codon (such as about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) of the native sequence with the codon more frequently or most frequently used in the genes of the host cell. Different species show specific preferences for certain codons of specific amino acids. Codon preference (the difference in the use of codons between organisms) is often related to the translation efficiency of messenger RNA (mRNA), and this translation efficiency is then considered to depend on the nature of the codons translated and the availability of specific transfer RNA (tRNA) molecules. The advantage of the tRNA selected in the cell generally reflects the codon most frequently used for peptide synthesis. Therefore, genes can be customized to the optimal gene expression based on codon optimization in a given organism. Codon utilization tables can be easily obtained, such as in the codon usage database ("Codon Usage Database") available on www.kazusa.orjp / codon / , and these tables can be adjusted and applied in different ways. See, Nakamura Y. et al., "Codon usage tabulated from the international DNA sequence databases: status for the year 2000. Nucl. Acids Res., 28:292 (2000).

[0132] On the other hand, the present invention also provides a truncated Csy4 recognition sequence element, the nucleotide sequence of which is shown in SEQ ID NO: 51. On the other hand, the present invention also provides a nucleic acid molecule such as an RNA molecule comprising the truncated Csy4 recognition sequence element. The RNA molecule is, for example, a gRNA, preferably a pegRNA. The gRNA and / or pegRNA are as defined above. On the other hand, the present invention also provides the use of the truncated Csy4 recognition sequence element in gene editing.

[0133] IV. Methods for Modifying Cell Genomic Sequences

[0134] In another aspect, the present invention provides a method for modifying the genomic sequence of a cell, comprising introducing the lead editing system of the present invention into at least one cell, thereby causing modification of the genomic sequence of the at least one cell. The modification comprises substitution, deletion, and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions. The modification can be located in the target sequence of the pegRNA or near the target sequence, for example, downstream of the target sequence.

[0135] In some embodiments, the lead editing system is introduced into the cell in the presence of one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole).

[0136] In some embodiments, after the lead editing system is introduced into the cell, the cell is treated with one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole), for example, the cell is cultured in a culture medium containing the one or more small molecule cyclic compounds (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole).

[0137] The concentration of nocodazole can be about 50 ng / ml to about 500 ng / ml, for example, about 100 ng / ml to about 300 ng / ml, preferably about 200 ng / mL. The concentration of RS-1 can be about 5 μM to about 50 μM, for example, about 10 μM to about 30 μM, preferably about 20 μM. The concentration of trichostatin A can be about 1 nM to about 50 nM, for example, about 5 nM to about 20 nM, preferably about 10 nM.

[0138] In another aspect, the present invention also provides a method for producing a genetically modified cell, comprising introducing the lead editing system of the present invention into the cell.

[0139] The genetic modification includes substitution, deletion and / or addition of one or more nucleotides. For example, the genetic modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, e.g., 1 to about 100 or more, e.g., 1 to about 100 or more, e.g., 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions. The modification can be located in the target sequence of the pegRNA or near the target sequence, for example, downstream of the target sequence.

[0140] In some embodiments, the lead editing system is introduced into the cell in the presence of one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA), preferably RS-1 and nocodazole.

[0141] In some embodiments, after the lead editing system is introduced into the cell, the cell is treated with one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably RS-1 and nocodazole), for example, the cell is cultured in a culture medium containing the one or more small molecule cyclic compounds (preferably RS-1 and nocodazole).

[0142] In another aspect, the present invention also provides a genetically modified organism comprising a genetically modified cell produced by the method of the present invention or a progeny cell thereof.

[0143] In the present invention, the modification can be located anywhere in the genome, for example, within a functional gene such as a protein-coding gene, or within a gene expression regulatory region such as a promoter region or an enhancer region, thereby modifying the gene function or gene expression. The modification in the cell genome sequence can be detected by T7EI, PCR / RE, or sequencing.

[0144] In the method of the present invention, the prime editing system can be introduced into cells by various methods well known to those skilled in the art.

[0145] Methods that can be used to introduce the lead editing system of the present invention into cells include, but are not limited to, calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection (such as baculovirus, vaccinia virus, adenovirus, adeno-associated virus, lentivirus and other viruses), gene gun method, PEG-mediated protoplast transformation, and Agrobacterium-mediated transformation.

[0146] Cells that can be gene-edited using the methods of the present invention can be derived from, for example, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, and cats; poultry such as chickens, ducks, and geese; and plants, including monocots and dicots, such as rice, corn, wheat, sorghum, barley, soybeans, peanuts, and Arabidopsis. In some preferred embodiments, the cells are derived from humans. In some preferred embodiments, the cells are derived from pigs.

[0147] In some embodiments, the methods of the present invention are performed in vitro. For example, the cells are isolated cells, or cells in isolated tissues or organs.

[0148] In other embodiments, the method of the present invention can also be performed in vivo. For example, the cell is a cell in an organism, and the system of the present invention can be introduced into the cell in vivo by, for example, a virus- or Agrobacterium-mediated method.

[0149] On the other hand, the present invention provides one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole) for use in lead editing, in particular for use in lead editing in mammalian cells.

[0150] 5. Therapeutic Applications

[0151] The present invention also encompasses the use of the lead editing system of the present invention in disease treatment.

[0152] By modifying the disease-related genes through the lead editing system of the present invention, it is possible to achieve upregulation, downregulation, inactivation, activation or mutation correction of the disease-related genes, thereby achieving the prevention and / or treatment of the disease. For example, the genomic modification described in the present invention can be located in the protein coding region of the disease-related gene, or, for example, can be located in a gene expression regulatory region such as a promoter region or an enhancer region, so as to achieve functional modification of the disease-related gene or modification of the expression of the disease-related gene. Therefore, the modified disease-related genes described herein include modification of the disease-related gene itself (e.g., protein coding region), and also include modification of its expression regulatory region (e.g., promoter, enhancer, intron, etc.).

[0153] "Disease-associated" gene refers to any gene that produces a transcription or translation product at an abnormal level or in an abnormal form in cells derived from tissues affected by the disease, compared to tissues or cells of non-disease controls. In the case where the altered expression is related to the appearance and / or progression of the disease, it can be a gene expressed at an abnormally high level; it can be a gene expressed at an abnormally low level. Disease-associated genes also refer to genes with one or more mutations or genetic variations that are directly responsible for or disequilibrium with one or more genes responsible for the etiology of the disease. The mutation or genetic variation is, for example, a single nucleotide variation (SNV). The transcribed or translated product can be known or unknown and can be at normal or abnormal levels.

[0154] Therefore, the present invention also provides a method for treating a disease in a subject in need thereof, comprising delivering an effective amount of the lead editing system of the present invention to the subject to modify a gene associated with the disease. The present invention also provides the use of the lead editing system in the preparation of a pharmaceutical composition for treating a disease in a subject in need thereof, wherein the lead editing system is used to modify a gene associated with the disease. The present invention also provides a pharmaceutical composition for treating a disease in a subject in need thereof, comprising the lead editing system of the present invention, and an optional pharmaceutically acceptable carrier, wherein the lead editing system is used to modify a gene associated with the disease.

[0155] Preferably, the pharmaceutical composition of the present invention further comprises one or more small molecule compounds selected from RS-1, nocodazole, and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole). In other preferred embodiments, the pharmaceutical composition of the present invention is used in combination with one or more small molecule compounds selected from RS-1, nocodazole, and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole).

[0156] Preferably, the "subject" of the present invention is a mammal, such as a human, mouse, rat, monkey, dog, pig, sheep, cow or cat, preferably a human.

[0157] In some embodiments, the prime editing systems described herein are used to introduce point mutations into nucleic acids.

[0158] In some embodiments, the lead editing system described herein is used to cause the correction of genetic defects, such as in point mutations that cause loss of function in gene products. In some embodiments, genetic defects are associated with diseases or conditions (e.g., lysosomal storage diseases or metabolic diseases, such as type I diabetes). In some embodiments, the methods provided herein can be used to introduce inactivating point mutations into genes or alleles encoding gene products associated with diseases or conditions.

[0159] In some embodiments, the purpose of the protocols described herein is to treat diseases associated with or caused by point mutations that can be corrected by the lead editing systems provided herein. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease.

[0160] In some embodiments, the methods described herein are intended to be used to treat mitochondrial diseases or disorders. As used herein, "mitochondrial diseases" refer to diseases caused by abnormal mitochondria, such as mutations in mitochondrial genes, enzyme pathways, etc. Examples of diseases include, but are not limited to, neurological diseases, loss of motor control, muscle weakness and pain, gastrointestinal diseases and difficulty swallowing, poor growth, heart disease, liver disease, diabetes, respiratory complications, epilepsy, vision / hearing problems, lactic acidosis, developmental delays, and susceptibility to infection.

[0161] Examples of diseases described herein include, but are not limited to, genetic diseases, circulatory system diseases, muscle diseases, brain, central nervous and immune system diseases, Alzheimer's disease, secretase disorders, amyotrophic lateral sclerosis (ALS), autism, trinucleotide repeat expansion disorders, hearing diseases, gene-targeted therapy of non-dividing cells (neurons, muscles), liver and kidney diseases, epithelial cell and lung diseases, cancer, Usher syndrome or retinitis pigmentosa-39, cystic fibrosis, HIV and AIDS, beta thalassemia, sickle cell disease, herpes simplex virus, autism, drug addiction, age-related macular degeneration, schizophrenia. Other diseases that are treated by correcting point mutations or introducing inactivating mutations into disease-related genes are known to those skilled in the art, and therefore the present disclosure is not limited in this regard. In addition to the diseases exemplarily described herein, other related diseases can also be treated using the strategies and lead editing systems provided by the present invention, and this application is obvious to those skilled in the art.

[0162] Administration of the lead editing system or pharmaceutical composition of the present invention can be adjusted based on the patient's or subject's weight and species. The frequency of administration is within the medically or veterinary acceptable range. It depends on conventional factors including the patient's or subject's age, sex, general health, other conditions, and the specific condition or symptom being addressed.

[0163] 6. Test Kit

[0164] The present invention also includes a kit for use in the methods of the present invention, the kit comprising the components of the lead editing system of the present invention. The kit may also contain reagents for introducing the lead editing system into an organism or a cell of an organism. The kit generally includes a label indicating the intended use and / or instructions for use of the contents of the kit. The term label includes any written or recorded material provided on or with the kit or otherwise provided with the kit. Example

[0165] Example 1: Acquisition and analysis of PERV-RT sequences.

[0166] Acquisition of PERV sequences: PERV-A / C (accession number: AY953542) and PERV-B (accession number: AY099324) sequences were obtained through the NCBI database. The positions and sequences of NC, RT and RNase H in the PERV sequences were analyzed using the conserved domain database to obtain PERV-AC-NC, PERV-B-NC, PERV-AC-RT (ΔRNase H) and PERV-B-RT (ΔRNase H).

[0167] Sequence Analysis: The DNA sequences of MMLV-RT (ΔRNase H), PERV-AC-RT (ΔRNase H), and PERV-B-RT (ΔRNase H) were converted into protein sequences and compared using MegAlign (V7.1.0) software (Figure 1). The results showed that PERV-AC-RT and PERV-B-RT were highly similar, differing in only 11 amino acids. In contrast, the similarity between PERV-RT and MMLV-RT was only 70%, with 153 and 150 amino acid differences between PERV-AC and PERV-B, respectively. Notably, of the four mutation sites in MMLV-RT in PE2, three shared homology with PERV-RT (Figure 1, red box). One site showed no homology, and the four consecutive bases at this site were not homologous to PERV-RT (Figure 1, black box).

[0168] Example 2: Construction of enhanced PERV-PE editor (epPE)

[0169] 2.1 Upgrade the PE2 editor and obtain PE2c-Puro

[0170] To enhance the efficiency of lead editing in mammalian cells, the present invention first upgraded the PE2 editor. The PE2 plasmid (number: #132775) was purchased from the Addgene plasmid sharing platform in the United States. Using the online codon optimization tool (https: / / www.genscript.com.cn / codon-opt.html), specific codon optimization was performed for the MMLV-RT in PE2 based on the porcine genome to obtain the MMLV-RT (condon opt) sequence. This sequence was then commissioned to Nanjing GenScript Biotechnology Co., Ltd. to synthesize and replace the MMLV-RT sequence of the PE2 vector to obtain the PE2c vector. In addition, the 2A-Puro sequence was synthesized and inserted into the C-terminus of the RT structure of the PE2c vector. The resulting vector was named PE2c-Puro (Figure 2).

[0171] 2.2 Construction of epPE editor.

[0172] 2.2.1 Construction of epPE-AC / B-m3-Puro

[0173] Using an online codon optimization tool (https: / / www.genscript.com.cn / codon-opt.html), specific codon optimization was performed on the PERV-AC-RT (ΔRNase H) and PERV-B-RT (ΔRNase H) sequences based on the porcine genome. Furthermore, corresponding mutations were made to the three mutation sites (M3) homologous to the MMLV-RT in PE2 (D200N, T306K, and W313F in MMLV-RT, corresponding to D199N, T305K, and W312F in PERV-RT). The PERV-AC-RT-M3Δ and PERV-B-RT-M3Δ sequences were obtained, respectively. The PERV-AC-RT-M3Δ and PERV-B-RT-M3Δ sequences were synthesized and replaced with the MMLV-RT in PE2c-Puro to obtain epPE-AC-M3Δ-Puro and epPE-B-M3Δ-Puro, respectively (Figure 2).

[0174] 2.2.2 Construction of epPE-AC / B-m4-Puro

[0175] Nanjing GenScript Biotechnology Co., Ltd. was commissioned to mutate amino acids 329-332 of RT in epPE-AC-M3Δ-Puro and epPE-B-M3Δ-Puro from EKGE to PGTL (DNA sequence mutated from GAGAAGGGTGAA / GAGAAGGGAGAG to CCAGGCACCCTG), resulting in epPE-AC-M4Δ*-Puro and epPE-B-M4Δ*-Puro ( Figure 2 ).

[0176] Example 3: Testing the Efficiency of Different epPEs in Immortalized BFP Fluorescent Reporter Porcine Fetal Fibroblast (PFF) Cells

[0177] 3.1 pegRNA and ngRNA construction

[0178] The pegRNA vector backbone pegRNA-GG (No.: 132777) and ngRNA vector backbone (No.: 107721) were purchased from the Addgene plasmid sharing platform in the United States, and the vector plasmid DNA was extracted using the Takata MidiBest Kit (Takara, China).

[0179] Vector digestion: A 30 μL reaction system containing 1× CutSmart buffer (Neb, USA), 1 μL of BsaI endonuclease (Neb, USA), and 2 μg of pegRNA-GG or ngRNA empty plasmid DNA was placed in a PCR instrument and digested at 37°C for 2 hours, followed by inactivation at 80°C for 15 minutes. The digestion products were separated on a 1.5% agarose gel and purified using the Axypre DNA Gel Extraction Kit (Axygen, USA).

[0180] The forward and reverse primers of pegRNA-gRNA, pegRNA 3'-extension, sgRNA scaffold, and ngRNA were annealed into double strands: a 25 μL reaction system containing 100 μM / L forward primer (F) and reverse primer (R), double-distilled water, and 1× T4 Ligation Buffer (Neb, USA) was added. The EP tube containing this reaction system was sealed and placed in a beaker filled with boiling water and slowly cooled to room temperature.

[0181] Ligation of pegRNA: The ligation system is shown in Table 1. After the system is prepared, it is placed at room temperature for 10 minutes, then transferred to a PCR instrument and incubated at 16°C for 5 minutes, 37°C for 15 minutes (8 cycles), and finally inactivated at 80°C for 15 minutes.

[0182] Table 1 pegRNA ligation system

[0183] ngRNA ligation: 1 μL of annealed ngRNA was ligated in 10 μL of Quick Ligase (Neb, USA) at room temperature for 15 minutes and then stored in a -20°C refrigerator.

[0184] Preparation of high-purity plasmid. Take 5 μL of the connected pegRNA / ngRNA and transform it into 5α competent cells (Qingke Biotechnology, China) were plated on solid LB plates (LB solid medium containing 10 g peptone, 5 g yeast extract, 10 g NaCl, 15 g agar powder, and 30 mg ampicillin per liter) and cultured overnight at 37°C. Six clones were selected for each pegRNA / ngRNA and expanded in 1 mL of liquid LB medium. 500 μL of the aliquot was sent to Qingke Biotechnology Co., Ltd. for Sanger sequencing (sequencing primer: U6-F: atggactatcatatgcttaccgta). Correctly ligated clones were selected and added to 200 mL of liquid LB medium and cultured overnight at 37°C in a shaker. High-purity, endotoxin-free plasmid DNA was extracted using the Takata MidiBest Kit (Takara, China).

[0185] 3.2 Cell culture, electroporation and puromycin selection.

[0186] 3.2.1 Cell culture

[0187] The immortalized BFP fluorescent reporter PFF cell line was cultured in high-glucose DMEM (Gibco, USA) supplemented with 12% fetal bovine serum ((v / v), Excell, China) and 1% penicillin-streptomycin ((v / v), BI, China). This cell line was established in our laboratory by first using CRISPR-Cas9 technology to site-specifically insert the SV40 large T antigen into the H11 safe harbor locus of primary Bama Xiang PFFs. Subsequently, CRISPR-Cas9 technology was used to site-specifically integrate the BFP vector into the Rosa26 safe harbor locus of the immortalized PFFs. Finally, the BFP fluorescent reporter PFF cell line was generated through serial passage.

[0188] 3.2.2 Electroporation

[0189] When the cell confluence reached 85-90%, the cells were digested with 0.125% trypsin (Gibco, USA) and counted using a hemocytometer. Approximately 4 × 10 5 The cells were placed in a 15 mL centrifuge tube and centrifuged at 200 × g for 5 minutes. After aspirating the supernatant, 20 μL Entranster-E electroporation solution (Ingen, China), 1 μg PE editor, 0.5 μg pegRNA, and 0.5 μg ngRNA were added. After mixing, the cell suspension was transferred to a 16-well electroporation strip (Lonza, Germany) and placed in the electroporation strip holder of the 4D-NucleofectorTM electroporator. PFF cells were electroporated twice continuously using the CA137 program. The electroporated cells were cultured in a 6-well cell culture dish. The culture medium was replaced 7 hours after electroporation to remove dead cells caused by electroporation.

[0190] 3.2.2 Puromycin drug screening

[0191] 48 hours after electroporation, 2 μg / mL puromycin (Sigma, Japan) was added for selection for 1 day, and then the culture medium was replaced and cultured for another 3 days.

[0192] 3.3 Editing efficiency detection

[0193] After digesting the cells with 0.125% trypsin (Gibco, USA), the cells were collected into a 1.5 mL EP tube and centrifuged at 200 × g for 5 minutes. The supernatant was discarded and 50 μL of 1 × PBS buffer was added to resuspend the cells. The cells were detected using a flow cytometer (BD, USA). Wild-type fluorescent reporter cells were used as the background, and GFP-positive cells were circled using the FITC+PE dual channel. The GFP ratio was the editing efficiency.

[0194] Flow cytometry analysis showed that the efficiency of the epPE editors derived from the four PERV-RTs was significantly higher (p < 0.01) than that of the mouse RT-derived PE2c-Puro editor. Furthermore, the efficiency of epPE-AC-M3Δ-Puro was higher than that of epPE-B-M3Δ-Puro (p = 0.007), and the efficiency of epPE-AC-M4Δ*-Puro was higher than that of epPE-B-M4Δ*-Puro (p = 0.012). (Figure 3)

[0195] Example 4: Testing the efficiency of type AC and type B PERV-RT epPE in primary PFF cells

[0196] 4.1 Obtaining primary PFF cells

[0197] Sows at 31 days of gestation were euthanized and then dissected. After the entire uterus was removed, the fetuses were removed one by one along with the fetal membranes and transferred to a DMEM solution containing 5% (v / v) penicillin and streptomycin (v / v; Gibco: 15140-122) and stored in a refrigerator at 4°C. In a clean bench, the separated fetuses were transferred one by one to a sterile 10 cm culture dish, and the head, internal organs, limbs and tail of the fetus were removed with sterile forceps and scissors; the remaining part of the fetus was cleaned with a PBS solution containing 5% (v / v) penicillin and streptomycin (Gibco: 15140-122) and minced to about 1 mm within 10-15 minutes. 3Add 5ml of collagenase working solution to the minced tissue; cut the tip of a 1ml sterile pipette tip with scissors, transfer the minced tissue to a 15ml sterile centrifuge tube, seal with parafilm, and incubate in a shaker at 37°C for 2 hours. Centrifuge the tube at 1000 rpm for 5 minutes, remove the upper layer of collagenase working solution, and evenly transfer the incubated tissue pieces to two T75 culture dishes and incubate in a sterile incubator at 37°C and 5% CO2. Continue incubation until the next morning (Note: If the cell culture medium turns yellow approximately 20 hours after the start of cell culture, replace it with fresh medium). Observe the cells under a microscope for adhesion and detachment from the tissue. Establishment of the primary porcine PFF cell line is complete when the cells reach a confluence of at least 85%. The cells can be frozen or subcultured.

[0198] 4.2 Primary PFF cell culture, electroporation and puromycin selection

[0199] The cells were cultured in high-glucose DMEM (Gibco, USA) supplemented with 12% (v / v) fetal bovine serum (Excell, China) and 1% (v / v) penicillin-streptomycin (BI, China) at 37°C in a 5% carbon dioxide incubator. When the cell confluence reached 85-90%, the cells were digested with 0.125% trypsin (Gibco, USA) and counted using a hemocytometer. For each electroporation reaction, 4 × 10^5 cells were placed in a 15 mL centrifuge tube and centrifuged at 200 × g for 5 minutes. The supernatant was aspirated and 20 μL of Entranster-E electroporation buffer (Ingen, China) was added, along with 1 μg of PE editor, 0.5 μg of pegRNA, and 0.5 μg of ngRNA. After mixing, the cell suspension was transferred to a 16-well electroporation strip (Lonza, Germany) and placed in the electroporation strip holder of a 4D-Nucleofector™ electroporator. The cells were electroporated twice using the CA-137 program. The electroporated cells were then cultured in 6-well cell culture dishes. The culture medium was changed 7 hours after electroporation to remove dead cells caused by electroporation. 2 μg / mL puromycin (Sigma, Japan) was added 48 hours after electroporation for selection for 1 day, and the culture medium was then changed and cultured for another 3 days.

[0200] 4.3 Editing efficiency detection

[0201] 4.3.1 Cell DNA Acquisition

[0202] The cells were digested with 0.125% trypsin and collected into a 200 μL EP tube. The tube was centrifuged at 750 × g for 5 minutes, and the supernatant was removed using a vacuum aspirator. 12 μL of cell lysis buffer (0.45% NP40 lysis buffer (Gibco, USA) and 6% proteinase K (Sigma, Japan)) was added to resuspend the cells and placed in a PCR instrument. The reaction program was: 56°C for 1.5 hours, and 85°C for 15 minutes.

[0203] 4.3.2 Target site amplification.

[0204] Two rounds of PCR amplification of the target loci were performed using the corresponding primers. The first round of PCR amplified the target loci, while the second round of PCR used labeled primers to label the sample. Both rounds of PCR were performed using PrimeSTAR Max DNA Polymerase (Takara, Japan). Each reaction contained 8 μL of PrimeSTAR Max DNA Polymerase buffer, 1 μL of each forward and reverse primer, 1 μL of DNA template, and 5 μL of ultrapure water. PCR reaction conditions were: 94°C for 5 minutes, followed by 26 cycles of (94°C for 30 seconds, 68°C (decreasing by 0.5°C each cycle) for 30 seconds, and 72°C for 1 minute), followed by 14 cycles of (94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute), and 72°C for 5 minutes.

[0205] 4.3.3 Sample Mixing and Gel Extraction Purification. Amplified products with different tags were mixed, with 5 μL of each sample and 8-12 samples per group. After adding loading buffer to the mixed samples, separate them on a 2% agarose gel at 180 V for 20 minutes. The target fragments were then cut on a UV-cleaving gel stage and purified using the Axypre DNA Gel Extraction Kit (Axygen, USA) according to the instructions. Finally, the DNA was dissolved in ultrapure water.

[0206] 4.3.4 High-throughput sequencing. Take 2 μg of the purified PCR product and send it to Beijing Novogene Technology Co., Ltd. for library construction and sequencing. First, use Ultra TM DNA was A-tailed and ligated with Illumina sequencing adapters using the DNA Library Prep Kit for Illumina. DNA was then purified using the AMPure XP system and quantified and diluted using the Qubit 3.0. The library inserts were detected using an Agilent 2100. For libraries with insert sizes that met the expected size, the effective concentration was accurately quantified using Q-PCR. Paired-end sequencing was then performed using the PE150 platform of the Illumina high-throughput NovaSeq 6000 sequencer.

[0207] 4.3.5 Editing efficiency analysis

[0208] First, Fastp (V0.19.7) software was used to filter out sequences with base quality values ​​Qphred ≤ 5 and N content in the read exceeding 10% of the number of bases in the read to obtain Clean Data. Fastq-multx (V1.31) software was used to split the mixed sample data, and R1.fastq and R2.fastq were obtained for each sample. CRISPResso2 (V2.0.43) software was used to analyze the editing efficiency. Parameters such as ref_seq, pegRNA_spacer_seq, pegRNA_extension_pegRNA_scaffold_seq, and nicking_guide_seq were provided for each sample, and the default values ​​were used for other parameters. Among them, ref_seq is the reference sequence amplified by PCR, and the pegRNA_extension_pegRNA_scaffold_seq sequence is the complete sgRNA scaffold sequence. For the final result, Prime-edited UNMODIFILED was considered as precise editing, and other editing types were considered as unwanted byproducts.

[0209] The results showed that at the six editing sites tested in primary PFFs, the average editing efficiency of the epPE editor derived from PERV-RT was higher than that of the PE2c-Puro editor derived from mouse RT, and the average efficiency of epPE-AC-M3Δ-Puro was higher than that of epPE-B-M3Δ-Puro (Figure 4).

[0210] Example 5: Testing the efficiency of epPE in other cells

[0211] 5.1 Cell culture

[0212] Canine fetal fibroblasts (DFF) were isolated from 30-day-gestation female fetuses using the same method as for PFFs. Sheep fetal fibroblasts (SFF) were donated by Wei Hongjiang's laboratory at Yunnan Agricultural University and were isolated from small-tailed Han sheep fetuses. 293T cells were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences. All three cell lines were cultured in high-glucose DMEM (Gibco, USA) supplemented with 12% (v / v) fetal bovine serum (Excell, China) and 1% (v / v) penicillin-streptomycin (BI, China) at 37°C in a 5% CO2 incubator.

[0213] 5.2 Cell transfection

[0214] DFF and SFF: The method is similar to the transfection method of PFF. The difference is that for DFF and SFF, after electroporation using the EN-150 program, electroporation is performed again using the CA-113 program.

[0215] 293T cells: 1-2 days before cell transfection, cells were seeded into 24-well culture dishes. When the cell confluence reached 50-60%, transfection was performed using Lipofectamine 3000 reagent (Invitrogen, USA). Each transfection reaction included 1 μg PE editor, 0.5 μg pegRNA, 0.5 μg ngRNA, and 1 μL Lipofectamine 3000 reagent.

[0216] 5.3 Puromycin Drug Screening

[0217] SFF and DFF cells: 48 hours after electroporation, 3 μg / mL puromycin (Sigma, Japan) was added for selection for 2 days, and then the culture medium was replaced and cultured for another 2 days.

[0218] 293T cells: 48 hours after transfection, 3 μg / mL puromycin (Sigma, Japan) was added for selection for 3 days, and then the culture medium was replaced and cultured for another 2 days.

[0219] 5.4 Editing Efficiency Detection

[0220] The method is consistent with the editing efficiency of PFF.

[0221] After analysis, as shown in Figure 5, the efficiency of the epPE editor in other mammals such as SFF, DFF and 293T is higher than that of the PE2c-Puro vector of mouse MMLV-RT.

[0222] Example 6: Application of RT of PERV Isolated from Bama Xiang Pig in Primer Editing

[0223] The inventors also isolated three types of PERV-RT (bmx-PERV-A-RT-M0, bmx-PERV-B-RT-M0, and bmx-PERV-C-RT-M0) from Bama Xiang pig DNA by PCR amplification, and replaced the MMLV-RT in the PE2c-Puro vector respectively to obtain pPE editors of three PERV-RTs, A, B, and C, respectively. PE editors carrying different mutation sites were constructed for bmx-PERV-RT; M0 represents the wild type and does not contain mutations; M4 represents 4 mutations (D199N, T305K, W312F, and L602W), as shown in Figure 6. The PERV-RT and corresponding lead editors isolated from Bama Xiang pigs are preceded by "bmx-" to distinguish them from the PERV-RT and corresponding lead editors from NCBI.

[0224] The editing activities of different editors were tested in different cell lines as described above.

[0225] Figure 7 shows that in the BFP reporter gene cell line, the pPE editor containing the Bama Xiang pig type C PERV reverse transcriptase has a higher editing activity, and after the introduction of mutations, the three PERV-RTs can all obtain higher editing activity.

[0226] Figure 8 shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in PFF, and bmx-pPE-C-M4-puro shows an overall higher efficiency.

[0227] Figure 9 shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in HEK293T, canine fetal fibroblasts, and sheep fetal fibroblasts. bmx-pPE-C-M4-puro showed higher efficiency at most sites.

[0228] Figure 10 shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase epPE editor containing 4 point mutations in PFF. Compared with type A and type B bmx-epPE, type C bmx-epPE editor shows an overall higher efficiency and is significantly higher than bmx-pPE.

[0229] Figure 11 shows the editing efficiency of the C-type bmx-epPE editor (bmx-epPE-C-M3Δ-Puro) in HEK293T, canine fetal fibroblasts, and sheep fetal fibroblasts. The overall editing efficiency of bmx-epPE-C-M3Δ-Puro in the three cell lines was significantly higher than that of bmx-pPE-C-M4-Puro.

[0230] Example 7: The PERV-RT lead editing system in the Maxiang pig carrying 7 point mutations has higher efficiency

[0231] Based on the known higher editing efficiency of type C bmx-PERV-RT in the lead editing system, the inventors screened a large number of mutation sites for type C bmx-PERV-RT in 293T cells.

[0232] 7.1 Selection of mutation sites

[0233] 7.1.1 Mutation sites that have been reported in the MMLV-RT prime editing system and share homology with PERV-RT.

[0234] According to the reports of Anzalone et al. Nature (2019) and Ni et al. Genome Biology (2023), sites that are effective in the MMLV-RT prime editing system and have homology with PERV-RT were selected, and six potential favorable sites were obtained: D199N, T305K, W312F, E329P, L602W and V222A.

[0235] 7.1.2 Use molecular docking to obtain potential favorable mutation sites.

[0236] Mutating the polar negatively charged amino acids (D, E) and polar uncharged amino acids (S, T, C, N, Q, Y, G) in RT that bind to DNA or RNA into polar positively charged amino acids (R, K) may enhance the interaction between RT and DNA / RNA and thus improve the efficiency of prime editing. To this end, the present invention used Phyre2 software to obtain the predicted protein structure of the bmx-PERV-C-RT-M5.1 variant, and downloaded the PDB file of the MMLV-RT-DNA-RNA complex: 4KHQ from the PDB database. The bmx-PERV-C-RT-M5.1 variant was aligned with 4KHQ using PyMOL software to find the amino acids that bmx-PERV-C-RT-M5.1 interacts with DNA / RNA, and all negatively polarized and uncharged amino acids were mutated to R, resulting in a total of 11 mutation sites: Y43R, Y108R, Q112R, D113R, E116R, D149R, D152R, G190R, N118R, N130R, G269R, T305R, and Y324R.

[0237] 7.1.3 Obtaining Potential Favorable Sites Based on Literature Reports

[0238] 7.1.3.1 Select mutation sites that have been reported to improve MMLV-RT reverse transcription performance but have not been validated in the PE system and that share homology with PERV-RT. A total of seven potential mutation sites were identified: S86R, Q112R, Q189F, Q220R, T286A, E332Q, and I434R.

[0239] 7.1.3.2 Doman et al. Cell (2023) used a phage-assisted evolution system to obtain a large number of mutation sites, but the efficiency of these mutation sites has not been verified in the PE system. The present invention screened out 9 high-frequency mutation sites that are homologous to PERV-RT: T127N, P131S, P195S, K232N, E338N, C408R, D423V, M456I, and T457I.

[0240] 7.2 293T cell fluorescent reporter gene co-transfection experiment

[0241] 17-24 hours before cell transfection, 1×10 5 Cells were seeded into 24-well culture dishes and transfected using H4000 reagent (Ingen, China) when the cell confluence reached 50-80%. Each transfection reaction included 200ng of PE editor, 100ng of pegRNA, 100ng of ngRNA, 10ng of fluorescent reporter gene vector, and 0.5μL of H4000 reagent. Cells were harvested 48 hours after transfection and analyzed using a flow cytometer (BD, USA). GFP-positive cells were circled using a FITC+PE dual channel with wild-type fluorescent reporter cells as the background. The GFP ratio was used as the editing efficiency.

[0242] 7.3 Editing experiments at endogenous editing sites in 293T cells

[0243] 17-24 hours before cell transfection, 1×10 5 Cells were seeded into 24-well culture dishes and transfected using H4000 reagent (Ingen, China) when the cells reached 50-80% confluence. Each transfection reaction consisted of 400 ng of PE editor, 200 ng of pegRNA, 200 ng of ngRNA, and 1 μL of H4000 reagent. The culture medium was replaced 24 hours after transfection, and cells were harvested approximately 72 hours after transfection. Editing efficiency was assessed using the method described in 4.3.

[0244] Figure 12 shows the efficiency of 6 mutation sites reported and homologous to PERV-RT in the C-type bmx-PERV-RT carrying MMLV-RT pilot editing system and their combinations in the 293T cell fluorescent reporter gene co-transfection experiment. The data show that the PERV-RT variant (named M5.1) carrying 5 amino acid mutations (D199N, T305K, W312F, L602W, V222A) exhibits the overall best efficiency among the three editing forms.

[0245] Figure 13 shows the efficiency of the M5.1-based pvPE editor in 293T cells by further superimposing new potential favorable mutation sites. Figure 13A shows the efficiency of a total of 27 new potential favorable sites reported in the literature using molecular docking in a 293T cell fluorescent reporter gene co-transfection experiment, of which 8 sites significantly reduced the PE editing efficiency. Figure 13B shows the efficiency of the remaining 19 mutation sites at endogenous sites in 293T cells, among which Y63R and C408R showed different degrees of improvement in editing efficiency.

[0246] Figure 14 shows the editing efficiency of M5.1, M5.1+Y63R, M5.1+C408R and its combination M5.1+Y63R+C408R (M7) at endogenous sites in 293T cells. The results show that M7 exhibits overlapping editing efficiency at multiple sites, and its efficiency at all sites is significantly better than that of M5.1.

[0247] Figure 15 shows the editing efficiency of the M7-based epPE editor in 293T cells. The efficiency of bmx-epPE-C-M7Δ superimposed with 7 point mutations is further improved compared to bmx-pPE-C-M7.

[0248] Figure 16 shows a comparison of the efficiency of bmx-epPE-C-M7Δ in 293T cells with the most efficient editors, including PEmax, PE6c, and PE6d. The results show that the overall efficiency of bmx-epPE-C-M7Δ is higher than that of PEmax, PE6c, and PE6d.

[0249] Example 8, tCsy4-pegRNA has higher editing efficiency

[0250] The 3' end of conventional pegRNA is a naked RNA, which is easily degraded in cells, thereby affecting the efficiency of pegRNA. In addition, since PBS is usually 10-16nt at the 3' end of pegRNA and is complementary to part of the spacer at the 5' end of pegRNA, their annealing is expected to cause pegRNA cyclization, which may hinder editing. It is reported that by adding the Csy4 recognition sequence (hairpin structure) to the end of pegRNA, the efficiency of PE in HKE293T, HeLa and Neuro-2a cells is significantly improved. The inventors also designed a truncated Csy4 (tCsy4, SEQ ID NO: 51). The editing efficiency of tCsy4-pegRNA was compared with that of Csy4-pegRNA and conventional pegRNA (Figure 17A). The results showed that the editing efficiency of Csy4-pegRNA (5 of 7 sites) and tCsy4-pegRNA (6 of 7 sites) was significantly higher than that of conventional pegRNA, and the editing efficiency of tCsy4-pegRNA was similar to or higher than that of Csy4-pegRNA (Figure 17B, C). In addition, the efficiency of tCsy4-pegRNA in HEK293T, DFF, and SFF was verified, and the data showed that tCsy4-pegRNA could further improve the PE efficiency in all three cell lines (Figure 17D).

[0251] Example 9: Small molecules can significantly improve the efficiency of lead editing in mammalian cells

[0252] Some small molecules are known to significantly enhance CRISPR / Cas9 genome editing efficiency. Based on this, we hypothesized that some small molecules might also enhance PE editing efficiency. We first tested nine small molecules with proven efficacy in the CRISPR / Cas9 system in a fluorescent reporter PFF cell line: 10μM Scr7, 2μM Nu7441, 25μM L189, 40μM L755507, 5μM Yu238259, 0.1μM Brefeldin A, 10nM TSA, 20μM RS-1, 200ng / mL Nocodazole, and 25μM L189. Following transfection, the cells were treated with the corresponding concentrations of each small molecule or combination of small molecules added to the culture medium.

[0253] The data showed that L755507, BrefeldinA, TSA, Rs-1 and Nocodazole significantly (P < 0.05 or P < 0.01) improved PE efficiency, among which TSA, Rs-1 and Nocodazole were more effective, increasing the editing efficiency by 34.4%, 32.7% and 66.9% (Figure 18A). Compared with the use of single molecules, the combination of Rs-1+TSA or Rs-1+Nocodazole significantly improved (P < 0.01) the editing efficiency. The Rs-1+Nocodazole group had the highest editing efficiency, with an efficiency increase of 106.0% compared with the DMSO group (Figure 18B). Then, the effects of Rs-1, Nocodazole, TSA and the combination of Rs-1+TSA and Rs-1+Nocodazole in primary PFFs were verified. The data showed that in primary PFFs using Rs-1, TSA, and Nocodazole, the overall editing efficiency of these six sites increased by 20.8%, 14.3%, and 36.4%, respectively. The Rs-1+Nocodazole combination increased the editing efficiency by 60.54%, while the Rs-1+TSA combination did not show an additive effect (Figure 18C). In addition, the efficiency of the Rs-1+Nocodazole combination in HEK293T, DFF, and SFF was verified, and the data showed that the Rs-1+Nocodazole combination could further improve PE efficiency in all three cell lines (Figure 18D).

[0254] Information on small molecule compounds involved in the present invention

[0255] RS-1:

[0256] Selleck Part Number: S8234,

[0257] MedChemExpress (MCE) Product Number: HY-19793

[0258] Chemical formula: C 20 H 16 Br2N2O3S

[0259] structure:

[0260] Nocodazole

[0261] Selleck Part Number: S2775

[0262] MedChemExpress (MCE) Product Number: HY-13520

[0263] Chemical formula: C 14 H 11 N3O3S

[0264] structure:

[0265] Trichostatin A (TSA)

[0266] Selleck Part Number: S1045

[0267] MedChemExpress (MCE) Product Number: HY-15144

[0268] Chemical formula: C 17 H 22 N2O3 structure:

[0269] Sequence information involved in the present invention

Claims

1. A lead editing system for targeted modification of an organism's genomic DNA sequence, comprising: i) (a) a CRISPR nuclease such as a CRISPR nickase and / or an expression construct comprising a nucleotide sequence encoding said CRISPR nuclease such as a CRISPR nickase, and a PERV reverse transcriptase or a functional variant thereof and / or an expression construct comprising a nucleotide sequence encoding said PERV reverse transcriptase or a functional variant thereof; or (b) a lead editing fusion protein and / or an expression construct containing a nucleotide sequence encoding the lead editing fusion protein, wherein the lead editing fusion protein comprises a CRISPR nuclease such as a CRISPR nickase and a PERV reverse transcriptase or a functional variant thereof; and / or ii) at least one pegRNA and / or an expression construct containing a nucleotide sequence encoding said at least one pegRNA, The at least one pegRNA comprises a leader sequence, a scaffold sequence, a reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence from 5' to 3' direction.

2. The prime editing system of claim 1, wherein the PERV reverse transcriptase is from type A, type B or type C PERV, or from a recombinant of a different type of PERV, such as a type A / C PERV recombinant.

3. The lead editing system of claim 1 or 2, wherein the PERV is a PERV isolated from Bama Xiang pig.

4. The lead editing system of any one of claims 1-3, wherein the PERV reverse transcriptase or a functional variant thereof comprises an amino acid sequence of one of SEQ ID NOs: 1-5 or an amino acid sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with one of SEQ ID NOs: 1-5.

5. The prime editing system of any one of claims 1 to 4, wherein the functional variant of the PERV reverse transcriptase lacks the RNase H domain.

6. The lead editing system of any one of claims 1-5, wherein the functional variant of the PERV reverse transcriptase comprises an amino acid substitution at one or more positions selected from position 63, 199, 222, 305, 312, 329, 330, 331, 332, 408 or 602.

7. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, and 312.

8. The prime editing system of claim 7, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, and W312F.

9. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, and 602.

10. The prime editing system of claim 9, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, and L602W.

11. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331 and 332.

12. The prime editing system of claim 11, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T and E332C.

13. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, 332, and 602.

14. The prime editing system of claim 13, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, E332C, and L602W.

15. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, and 602.

16. The prime editing system of claim 15, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, and L602W.

17. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, and 602.

18. The prime editing system of claim 17, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, and L602W.

19. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, 408 and 602.

20. The prime editing system of claim 19, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, C408R, and L602W.

21. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, 408 and 602.

22. The prime editing system of claim 13, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, C408R, and L602W.

23. The prime editing system of any one of claims 1-4, wherein the functional variant of the PERV reverse transcriptase comprises an amino acid sequence of one of SEQ ID NOs: 6-17 or 40-44.

24. The prime editing system of any one of claims 1 to 23, wherein in the fusion protein, the reverse transcriptase or a functional variant thereof is fused to a nucleocapsid protein (NC) at the N-terminus or the C-terminus directly or through a linker.

25. The prime editing system of claim 24, wherein the nucleocapsid protein (NC) is derived from PERV, preferably, the nucleocapsid protein and the reverse transcriptase are derived from the same type of PERV.

26. The prime editing system of claim 24 or 25, wherein the nucleocapsid protein comprises the amino acid sequence shown in one of SEQ ID NOs: 19 or 36-39.

27. The lead editing system of any one of claims 24-26, wherein the PERV reverse transcriptase or a functional variant thereof is fused to the nucleocapsid protein (NC) at the N-terminus directly or through a linker.

28. The lead editing system of any one of claims 1-27, wherein the CRISPR nuclease, such as CRISPR nickase, and the PERV reverse transcriptase or a functional variant thereof in the lead editing fusion protein are connected via a linker.

29. The lead editing system of any one of claims 1-28, wherein the CRISPR nickase is a Cas9 nickase, for example, the Cas9 nickase comprises the amino acid sequence shown in SEQ ID NO:

18.

30. The prime editing system of any one of claims 1-29, wherein the CRISPR nuclease, such as a CRISPR nickase, in the fusion protein is located at the N-terminus of the reverse transcriptase or a functional variant thereof.

31. The prime editing system of any one of claims 1-30, wherein the fusion protein further comprises a nuclear localization sequence (NLS).

32. The prime editing system of any one of claims 1-31, wherein the fusion protein may further include a selectable marker protein linked directly or via a self-cleavable peptide.

33. The lead editing system of claim 32, wherein the self-cleaving peptide is a 2A polypeptide and the selectable marker protein is a Puro-R protein.

34. The prime editing system of claim 1, wherein the fusion protein comprises an amino acid sequence shown in one of SEQ ID NOs: 22-34 or SEQ ID NOs: 45-49.

35. The lead editing system of any one of claims 1-34, wherein the at least one pegRNA is capable of forming a complex with the fusion protein and targeting the fusion protein to a target sequence in the genome, resulting in a nick within the target sequence.

36. The lead editing system of any one of claims 1 to 35, wherein the lead sequence in at least one pegRNA is configured to have sufficient sequence identity with the target sequence, preferably 100% identity, so that it can bind to the complementary strand of the target sequence through base pairing to achieve sequence-specific targeting.

37. The lead editing system of any one of claims 1-36, wherein the scaffold sequence is shown in SEQ ID NO:

21.

38. The prime editing system of any one of claims 1 to 37, wherein the primer binding sequence is set to be complementary to at least a portion of the target sequence, preferably, the primer binding sequence is complementary to at least a portion of the 3' free single strand caused by the nick, in particular, complementary to the nucleotide sequence at the 3' end of the 3' free single strand.

39. The lead editing system of any one of claims 1 to 38, wherein The RT template sequence is set to correspond to the sequence downstream of the nick and contains the desired modification, which includes substitution, deletion and / or addition of one or more nucleotides.

40. The lead editing system of any one of claims 1-39, further comprising a nicking gRNA and / or an expression construct containing a nucleotide sequence encoding the nicking gRNA, wherein the nicking gRNA comprises a leader sequence and a scaffold sequence, wherein the leader sequence is configured to have sufficient sequence identity with a target sequence in the genome so as to be able to target the fusion protein to the target sequence and cause a nick within the target sequence, wherein the target sequence of the nicking gRNA and the target sequence of the pegRNA are located on opposite strands of the genomic DNA, and the nick induced by the nicking gRNA and the nick induced by the pegRNA are approximately 1 to approximately 300 nucleotides apart.

41. The lead editing system of any one of claims 1-40, comprising at least one pair of pegRNAs and / or an expression construct comprising a nucleotide sequence encoding the at least one pair of pegRNAs.

42. The lead editing system of claim 41, wherein the two pegRNAs in the pegRNA pair are configured to target different target sequences on the same strand of genomic DNA, or the two pegRNAs in the pegRNA pair are configured to target target sequences on different strands of genomic DNA.

43. The lead editing system of any one of claims 41-42, wherein the two pegRNAs in the pegRNA pair are configured to introduce the same desired modification. The lead editing system of any one of 44. claims 1-43, wherein the pegRNA comprises the Csy4 recognition sequence of the brachymemma shown in SEQ ID NO:51 at 3' end.

45. A method for producing genetically modified cells, comprising introducing the lead editing system of any one of claims 1-44 into at least one of the cells, thereby resulting in modification of the genomic sequence of the at least one cell.

46. ​​The method of claim 45, wherein the lead editing system is introduced into the cell in the presence of one or more small molecule compounds selected from RS-1, nocodazole and trichostatin A (TSA), preferably RS-1 and nocodazole; or After the lead editing system is introduced into the cells, the cells are treated with one or more small molecule compounds selected from RS-1, nocodazole and trichostatin A (TSA) (preferably RS-1 and nocodazole), for example, the cells are cultured in a culture medium containing the one or more small molecule cyclic compounds (preferably RS-1 and nocodazole).

47. The method of claim 45 or 46, wherein the cell is from a mammal, such as a human, mouse, rat, monkey, dog, pig, sheep, cow, cat.

Citation Information

Patent Citations

  • Methods and compositions for prime editing nucleotide sequences

    US11447770B1

  • Method to enhance gene editing

    US20230070047A1

  • Method for producing genetically modified cells

    WO2022148955A1

  • Prime editing composition with improved editing efficiency

    WO2022169235A1

  • Improved prime editors and methods of use

    WO2023015309A2

Cited By

  • Pilot editing system based on PERV reverse transcriptase

    CN118995664A

  • Pilot editing system based on perv reverse transcriptase

    CN118995664B

  • Protein for guiding editing and application thereof

    CN120173141A

  • Construction method of Alzheimer's disease model pig based on endogenous multi-gene editing

    CN120536504A

  • Fusion protein expression cassette for rice multi-gene editing and application of fusion protein expression cassette

    CN121137039A